SAVA - Cassava Sciences Inc

https://www.cassavasciences.com

Momentum: Bearish

Recent News

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences ( SAVA ) Looks Ripe for a Turnaround

Zacks Commentary • 5 months, 2 weeks ago • score: 0.23

The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...

Bearish

Is the Future Bleak for SAVA Stock Following Another Setback?

Zacks Commentary • 5 months, 2 weeks ago • score: -0.38

The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas.

52W High

$33.98

52W Low

$1.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-2.07

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

151.52

EV/EBITDA (<8 favorable)

-8.26

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.19

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

12.79%

Institutions (25–75% balanced)

25.19%

Shares Outstanding

48,307,900

Float

43,475,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

2012-12-13

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

-56,988,000

EPS (TTM)

-2.63

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.89%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0349

-0.0295

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025